Susceptibility of archaea to antimicrobial agents: applications to clinical microbiology

Authors

  • S. Khelaifia,

    1. Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UMR CNRS 6236 IRD 3R198, Méditerranée Infection, Faculté de Médecine, Aix-marseille-Université, Marseille, France
    Search for more papers by this author
  • M. Drancourt

    1. Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UMR CNRS 6236 IRD 3R198, Méditerranée Infection, Faculté de Médecine, Aix-marseille-Université, Marseille, France
    Search for more papers by this author

Corresponding author: M. Drancourt, Unité des Rickettsies, Faculté de Médecine, 27, Boulevard Jean Moulin-Cedex 5, France
E-mail: michel.drancourt@univmed.fr

Abstract

Clin Microbiol Infect 2012; 18: 841–848

Abstract

We herein review the state of knowledge regarding the in vitro and in vivo susceptibility of archaea to antimicrobial agents, including some new molecules. Indeed, some archaea colonizing the human microbiota have been implicated in diseases such as periodontopathy. Archaea are characterized by their broad-spectrum resistance to antimicrobial agents. In particular, their cell wall lacks peptidoglycan, making them resistant to antimicrobial agents interfering with peptidoglycan biosynthesis. Archaea are, however, susceptible to the protein synthesis inhibitor fusidic acid and imidazole derivatives. Also, squalamine, an antimicrobial agent acting on the cell wall, proved effective against human methanogenic archaea. In vitro susceptibility data could be used to design protocols for the decontamination of complex microbiota and the selective isolation of archaea in anaerobic culture.

Ancillary